Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05918978 · ClinicalTrials.gov registry record · Phase 2
Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS
A Phase 2 study, sponsored by argenx.
- Terminated
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT05918978: Clinical Trial Phase 2 study, sponsored by argenx.
NCT05918978 is a Phase 2 study that was terminated before completion, run by argenx. The registered enrollment target is 33 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05918978, a Phase 2 study, was terminated before completion, sponsored by argenx.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
The OLE study aims to investigate the safety, efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity of efgartigimod in participants with post-COVID-19 postural orthostatic.
Primary Outcome
An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. A serious adverse event (SAE) was any untoward medical occurrence that at any dose resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or
Interventions
- DRUG Efgartigimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2023-06-20 |
| Est. Completion | 2024-08-15 |
| Phase | Phase 2 |
Why NCT05918978 stopped before completion
NCT05918978 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 1 intervention - of which Efgartigimod is the first listed.
NCT05918978 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05918978 about?
NCT05918978 is a clinical study titled "Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS". The OLE study aims to investigate the safety, efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity of efgartigimod in participants with post-COVID-19 postural orthostatic.
What is the current status of trial NCT05918978?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2023-06-20. Estimated completion is 2024-08-15.
What interventions are being tested in trial NCT05918978?
The interventions under investigation include: Efgartigimod (DRUG).
Who is sponsoring clinical trial NCT05918978?
This trial is sponsored by argenx, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05918978's enrollment target sits among peer trials
33 1553rd of 2000 higher than 438 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI